News stories about Insulet Corporation (NASDAQ:PODD) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insulet Corporation earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 92 out of 100, indicating that recent media coverage is extremely likely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Insulet Corporation (NASDAQ:PODD) & Delcath Systems (DCTH) Head to Head Comparison (americanbankingnews.com)
- Insulet Corporation (NASDAQ:PODD) Lowered to Neutral at BTIG Research (americanbankingnews.com)
- Insulet Corporation (PODD) Earns “Buy” Rating from Jefferies Group LLC (americanbankingnews.com)
- Cowen and Company Reiterates “Buy” Rating for Insulet Corporation (PODD) (americanbankingnews.com)
- Insulet Corporation to Announce Second Quarter 2017 Financial Results on August 3, 2017 (finance.yahoo.com)
Shares of Insulet Corporation (NASDAQ PODD) traded down 1.232% during midday trading on Monday, reaching $50.105. 118,054 shares of the company were exchanged. The company has a 50 day moving average price of $44.24 and a 200-day moving average price of $42.55. The stock’s market capitalization is $2.90 billion. Insulet Corporation has a 12-month low of $30.69 and a 12-month high of $52.48.
Insulet Corporation (NASDAQ:PODD) last posted its quarterly earnings results on Monday, May 8th. The medical instruments supplier reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Insulet Corporation had a negative return on equity of 48.46% and a negative net margin of 6.81%. The business had revenue of $101.70 million during the quarter, compared to the consensus estimate of $97.73 million. During the same quarter in the previous year, the company earned ($0.19) earnings per share. The company’s revenue for the quarter was up 25.2% compared to the same quarter last year. On average, analysts forecast that Insulet Corporation will post ($0.48) earnings per share for the current fiscal year.
Several analysts have recently issued reports on PODD shares. Jefferies Group LLC reiterated a “buy” rating and issued a $53.00 target price on shares of Insulet Corporation in a research note on Thursday, April 13th. Northland Securities restated a “buy” rating and set a $50.00 price target on shares of Insulet Corporation in a research report on Tuesday, May 9th. BTIG Research upgraded shares of Insulet Corporation from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Wednesday, May 10th. Cowen and Company restated a “buy” rating and set a $52.00 price target on shares of Insulet Corporation in a research report on Friday. Finally, ValuEngine upgraded shares of Insulet Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $47.00.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2722649/somewhat-favorable-news-coverage-extremely-likely-to-impact-insulet-corporation-podd-share-price.html.
In other news, Director David A. Lemoine sold 1,524 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $43.40, for a total transaction of $66,141.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Bradley A. Thomas acquired 3,000 shares of the firm’s stock in a transaction dated Thursday, May 11th. The shares were purchased at an average cost of $38.69 per share, for a total transaction of $116,070.00. The disclosure for this purchase can be found here. Insiders have bought a total of 8,080 shares of company stock worth $317,339 over the last ninety days. Insiders own 2.60% of the company’s stock.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.